Orna Therapeutics, a Cambridge, Mass.-based RNA therapy developer, has closed $121 million toward a targeted $221 million Series B round. New investor Merck joined founding investors MPM Capital and BioImpact Capital in the new funding.
Senda Biosciences Inc., a Cambridge, Mass.-based startup harnessing nature to program targeted medicines, closed a $123 million Series C round. Previous backers Flagship Pioneering, Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment and State of Michigan Retirement System were joined by new investors Samsung Life Science Fund, Qatar Investment Authority, Bluwave Capital and Stage 1 Ventures in the round.
Incredible Health, a San Francisco-based career marketplace for healthcare workers, secured $80 million in Series B financing led by Base10 Partners, bringing the company’s valuation to $1.65 billion. New investors including Rethink Impact and Stardust Equity also participated in the round, along with existing backers Andreessen Horowitz and Obvious Ventures.
Bluejay Therapeutics Inc., a San Mateo, Calif.-based startup developing a treatment for chronic HBV infection, completed a $41 million Series B round. Arkin Bio Ventures led the investment, which included contributions from Synergenics, RiverVest Venture Partners, Octagon Capital and InnoPinnacle International. Synergenics’ William J. Rutter, Arkin Bio Ventures’ Alon Lazarus and Octagon Capital’s Ting Jia were added to Bluejay’s board.
Moximed Inc., a Fremont, Calif.-based developer of an implantable shock absorber for people with knee osteoarthritis, raised $40 million in Series C equity and debt funding. Advent Life Sciences led the investment, which saw participation from New Enterprise Associates, Future Fund, Vertex Healthcare, Gilde Healthcare, GBS Venture Partners and Morgenthaler Ventures. Debt was provided by Runway Growth Capital.
Arine, a San Francisco-based medication intelligence startup, landed $29 million in Series B equity and debt funding. Led by 111° West Capital, the round included additional support from MBX Capital, New Leaf Venture Partners, Katalyst Ventures and Super Capital Group.
KeyCare Inc., a Chicago-based virtual care platform, picked up $24 million in Series A funding from 8VC, LRVHealth, Bold Capital Partners and Spectrum Health Ventures.
Dr. B, a New York-based telehealth startup, snagged an $8 million investment from Lerer Hippeau, Founders Fund and others.
Love, a Miami-based startup seeking to develop new treatments and healing technologies based on community feedback, was seeded with a $7.5 million investment at a $180 million valuation. Human Capital and MaC Venture Capital were the investors. In addition to the funding, the company appointed Kevin Horgan as chief medical officer and Stacy McIntosh as chief regulatory officer.
Prolocor Inc., a startup developing a precision diagnostic test with the potential to predict the risk of thrombosis, snagged a $3.2 million seed investment led by Green Park & Golf Ventures. In addition to the funding round, Prolocor received a $2 million Phase II grant from the Small Business Innovation Research program of the National Institutes of Health.
|